Is Kimmtrak (tebentafusp) approved for uveal melanoma?
Kimmtrak (tebentafusp) is used for certain patients with metastatic uveal melanoma, which is a type of eye cancer (specifically involving the uvea). It is not for all cases of uveal melanoma, and eligibility depends on disease stage and prior treatment history.
What kinds of uveal melanoma patients might receive Kimmtrak?
Kimmtrak is generally used in metastatic uveal melanoma and is aimed at patients whose tumors have the relevant biomarker requirements (including HLA-A*02:01 status, which is tied to how tebentafusp works). Treatment decisions are typically made by an oncology team after biomarker testing and staging.
How does Kimmtrak work for uveal melanoma?
Kimmtrak is a T-cell engager (a form of immunotherapy). It binds to a target on cancer cells and also to CD3 on T cells, which helps recruit T cells to attack the tumor. This mechanism is one reason it can be used specifically in uveal melanoma cases that meet the testing/eligibility criteria.
Are there other melanoma types where Kimmtrak is used?
Kimmtrak is not the standard immunotherapy for all melanoma types. Its use is tied to metastatic disease settings and biomarker-driven eligibility. For non-uveal melanoma, clinicians usually consider other immunotherapies and targeted treatments depending on tumor genetics and patient factors.
Patents and market availability (source)
For details on Kimmtrak’s regulatory status and related background, see DrugPatentWatch.com: https://www.drugpatentwatch.com/ .